PRTA 8.55 ▲ 4.14% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Prothena Corporation

    NASDAQ: PRTA · Real-Time Price · USD
    8.55
    0.34 (4.14%)
    At close: Sep 05, 2025, 3:59 PM
    8.55
    0.00%
    After-hours: Sep 05, 2025, 05:34 PM EDT
    4.14%
    Bid 8.06
    Market Cap 460.25M
    Revenue (ttm) 10.34M
    Net Income (ttm) -302.92M
    EPS (ttm) -5.62
    PE Ratio (ttm) -1.52
    Forward PE 54.73
    Analyst Hold
    Ask 8.92
    Volume 1,107,581
    Avg. Volume (20D) 1,258,572
    Open 8.36
    Previous Close 8.21
    Day's Range 8.21 - 8.59
    52-Week Range 4.32 - 22.71
    Beta -0.04

    About PRTA

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol PRTA
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for PRTA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Prothena Corporation is scheduled to release its earnings on Nov 11, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 week ago
    +2.51%
    PRTA stock has given up its prior loss. Prothena s... Unlock content with Pro Subscription
    1 week ago
    +2.51%
    Prothena shares are trading lower after the company reported Phase 1 results for PRX012.
    news image

    4 days ago · zacks.com

    Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?

    Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

    news image

    1 month ago · businesswire.com

    Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

    DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.

    news image

    1 month ago · fool.com

    Prothena Q2 Revenue Drops 97%

    Prothena (PRTA 3.96%), a biotechnology company focused on developing therapies for neurodegenerative diseases, released its second quarter 2025 results on August 4, 2025. The period saw notably weaker...

    news image

    1 month ago · zacks.com

    Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates

    Prothena (PRTA) came out with a quarterly loss of $1.86 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to earnings of $1.22 per share a year ago.

    news image

    1 month ago · businesswire.com

    Prothena to Report Second Quarter 2025 Financial Results on August 4

    DUBLIN--(BUSINESS WIRE)--Prothena today announced that it will report its second quarter and first six months of 2025 financial results on August 4, 2025.

    news image

    2 months ago · zacks.com

    PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?

    Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.

    news image

    2 months ago · businesswire.com

    Prothena Announces Corporate Restructuring

    DUBLIN--(BUSINESS WIRE)--Prothena announced that the Company has initiated an approximate 63% reduction in its workforce.

    news image

    2 months ago · businesswire.com

    Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

    DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson's disease.

    Add to Watchlist